Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mood Effects of Serotonin Agonists: Depression

NCT07017478
View directory record Official record
Conditions
LSD, Major Depressive Disorder, Depression
Interventions
LSD, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880048
View directory record Official record
Conditions
Depressive Disorder
Interventions
orvepitant, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional

fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI

NCT02980484
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Active, Sham
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 16, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Activating Voice Journaling for Mental Health With Voice Biomarkers

NCT07789808
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Anxiety
Interventions
Not listed
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

NCT04479852
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence

NCT00149643
View directory record Official record
Conditions
Depressive Disorder, Major, Cannabis Abuse
Interventions
Fluoxetine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 25 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 16, 2026, 11:07 AM EDT
Not listed Early Phase 1 Interventional

Ketamine for Mood Disorders With Suicidal Ideation

NCT04099771
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal Ideation
Interventions
Ketamine
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 16, 2026, 11:07 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 16, 2026, 11:07 AM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated No phase listed Observational

A Prospective Study of Postpartum Depression in Women With Major Depression

NCT01328613
View directory record Official record
Conditions
Postpartum Depression
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated Not applicable Interventional

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

NCT00655226
View directory record Official record
Conditions
Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions
Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Oct 16, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complex Dynamic Systems in Mood Disorders

NCT01583569
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression

NCT00961454
View directory record Official record
Conditions
Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions
Photobiomodulation with a super-luminous light emitting diode
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

NCT01944969
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 16, 2026, 11:07 AM EDT
Completed No phase listed Observational

Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder

NCT00869505
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Oct 16, 2026, 11:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

NCT07560631
View directory record Official record
Conditions
Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions
SeeMe Multimodal Auditory Command Protocol
Diagnostic Test
Lead sponsor
Stony Brook University
Other
Eligibility
22 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression (ALTO-300-004)

NCT05157945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Jackson, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 16, 2026, 11:07 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Rescuing the Ruminating Brain: Identifying Biomarkers of Rumination and Mindfulness Through Concurrent EEG and Functional Magnetic Resonance Imaging (fMRI) Studies of Schizophrenia and Depression

NCT03758495
View directory record Official record
Conditions
Schizophrenia, Depressive Disorder, Major
Interventions
Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot BA Study of New LY03005 vs Pristiq

NCT02988024
View directory record Official record
Conditions
Major Depression
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 16, 2026, 11:07 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Blinded capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 16, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence

NCT01874951
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 16, 2026, 11:07 AM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 16, 2026, 11:07 AM EDT